Attached To Peptide Or Protein Of 2+ Amino Acid Units (e.g., Dipeptide, Folate, Fibrinogen, Transferrin, Sp. Enzymes); Derivative Thereof Patents (Class 424/1.69)
-
Patent number: 8383578Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.Type: GrantFiled: June 24, 2011Date of Patent: February 26, 2013Assignee: CureDM Group Holdings, LLCInventors: Claresa S. Levetan, Loraine V. Upham
-
Patent number: 8383772Abstract: The application provides Ang-(1-7) receptor agonist peptides and their use for treating acute lung injury.Type: GrantFiled: August 21, 2012Date of Patent: February 26, 2013Assignee: Charite Universitatsmedizin BerlinInventors: Thomas Walther, Wolfgang Kuebler
-
Patent number: 8383082Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.Type: GrantFiled: August 21, 2012Date of Patent: February 26, 2013Assignees: GP Medical, Inc., National Tsing Hua UniversityInventors: Hsing-Wen Sung, Kiran Sonaje, Hosheng Tu
-
Patent number: 8383575Abstract: A complex comprising barnase bound with high affinity to barstar, and comprising a therapeutic and/or diagnostic agent bound to barnase and/or barstar.Type: GrantFiled: January 31, 2005Date of Patent: February 26, 2013Assignee: Paul Scherrer InstitutInventors: Sergey Deyev, Robert Waibel, Andreas Plueckthun
-
Patent number: 8383083Abstract: One aspect of the present invention relates to novel compounds that can be used to prepare radiolabeled compounds in an effective manner. A second aspect of the present invention relates to a method of synthesizing radiolabeled compounds.Type: GrantFiled: June 30, 2011Date of Patent: February 26, 2013Assignee: University of Western OntarioInventors: Duncan H. Hunter, Mustafa Janabi
-
Publication number: 20130045161Abstract: A new approach to targeting imaging agents to macrophage-rich sites of interest is disclosed. Compositions of the invention are rHDL and HDL-like liposomal compositions, protein constituents of which, apolipoproteins A-I and/or A-II or fragments thereof are used not only as structural but also as targeting agents. This is achieved by certain controlled chemical or enzymatic modification of apolipoproteins A-I or A-II or fragments thereof. Such modification converts these apolipoproteins to substrates for macrophage scavenger receptors and results in the improvement of contrast agent-(HDL/modified apolipoprotein)-particle association with macrophages and/or absorption (uptake) by macrophages when compared to that of the contrast agent-(HDL/apolipoprotein)-particle constructed with non-modified naturally occurring apo A-I.Type: ApplicationFiled: October 10, 2010Publication date: February 21, 2013Applicant: SIGNABLOK, INC.Inventor: Alexander B. Sigalov
-
Patent number: 8377865Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I), and pharmaceutically acceptable salts thereof, that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2 (I) or a pharmaceutically acceptable salt thereof, wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.Type: GrantFiled: June 9, 2008Date of Patent: February 19, 2013Assignee: IPSEN Pharma S.A.S.Inventor: Zheng Xin Dong
-
Patent number: 8377868Abstract: The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to auto oxidation and superior oxygen carrying characteristics.Type: GrantFiled: July 11, 2011Date of Patent: February 19, 2013Assignee: Sangart, Inc.Inventors: Robert M. Winslow, Kim D. Vandegriff
-
Patent number: 8378071Abstract: The disclosure provides antigenic peptides of Vascular Endothelial Growth Factor Receptor 2(VEGFR-2)/KDR. Pharmaceutical compositions including the peptides and/or antigen presenting cells that exhibit the VEGFR-2/KDR peptides on their cell surface are also provided. Methods for eliciting an immune response and for inhibiting angiogenesis by administering such pharmaceutical compositions are provided.Type: GrantFiled: March 11, 2009Date of Patent: February 19, 2013Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Samir N. Khleif, Yujun Dong
-
EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS
Publication number: 20130039853Abstract: Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.Type: ApplicationFiled: July 31, 2012Publication date: February 14, 2013Inventors: David J. Yang, Dongfang Yu, Andrew S. Thompson, F. David Rollo -
Patent number: 8372800Abstract: An albumin-free Factor VIII formulation comprising: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.Type: GrantFiled: September 30, 2011Date of Patent: February 12, 2013Assignees: Baxter International Inc., University of ConnecticutInventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
-
Patent number: 8367039Abstract: The present invention relates to a compound of the following general formula (I): Signal-Linker-Peptide (I) in which Signal is a signal entity; Linker, is absent or is a chemical bond, and Peptide is a peptide having a VCAM-targeting peptide and pharmaceutically acceptable salts thereof. The VCAM-targeting peptide may be X10-X11-X12-X13-X14-X15-X16-X17-X18 (SEQ ID No. 4) with X10 chosen from cysteine and methionine; X11 chosen from methionine and cysteine; X12 chosen from lysine, arginine and alanine; X13 chosen from threonine and serine; X14 chosen from aspartic acid and glutamic acid; X15 chosen from threonine and serine; X16 chosen from arginine, alanine and lysine; X17 chosen from leucine, isoleucine and valine; X18 chosen from cysteine and methionine; preferably, the peptide CMKTDTRLC (SEQ ID No. 5).Type: GrantFiled: March 28, 2008Date of Patent: February 5, 2013Assignee: GuerbetInventors: Marc Port, Olivier Rousseaux, Robert Muller, Carmen Burtea
-
Publication number: 20130028836Abstract: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.Type: ApplicationFiled: February 4, 2011Publication date: January 31, 2013Applicant: MORPHOTEK, INC.Inventors: Abdellah Sentissi, Douglas B. Jacoby
-
Patent number: 8361443Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.Type: GrantFiled: June 15, 2005Date of Patent: January 29, 2013Assignee: GE Healthcare ASInventor: Alan Cuthbertson
-
Patent number: 8361969Abstract: The present invention is concerned with a novel composition of matter—a cyclic peptide derived from computer modeling studies that modulates the structure and function of the HIV main envelope protein gp120. The compound is capable of binding to the CD4-binding region of gp120 (this defines it as a CD4 mimic), and can be used for the purposes of: (1) controlling and preventing HIV infections, (2) detecting, isolating and purifying gp120. Contrary to examples of prior art that involved CD4 mimics being either small molecules or macromolecules, the present invention is concerned with the class of “large small molecules” that may offer a satisfactory balance between the activity and drug-like properties. Modified variants of the prototype compound that can be reasonably considered its derivatives are also claimed.Type: GrantFiled: April 20, 2012Date of Patent: January 29, 2013Inventor: Przemyslaw Czyryca
-
Patent number: 8361439Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.Type: GrantFiled: August 20, 2012Date of Patent: January 29, 2013Assignees: GP Medical, Inc., National Tsing Hua UniversityInventors: Hsing-Wen Sung, Kiran Sonaje, Zi-Xian Liao, Ha Giang Thi Nguyen, Er-Yuan Chuang, Hosheng Tu
-
Patent number: 8354512Abstract: A ligand of Formula (I) is provided: wherein A4 represents a hydrogen atom, a nitro group, an amino group, a thiocyanato group, or —Z—Y, in which Z is a divalent linking group and Y is a group derived from a biocompatible molecule, with the proviso that when X is methylene, A4 cannot be a hydrogen atom or a nitro group. A metal complex having the ligand is also provided and is useful as a blood pool contrast agent or a targeting contrast agent.Type: GrantFiled: February 8, 2010Date of Patent: January 15, 2013Assignee: National Chiao Tung UniversityInventors: Yun-Ming Wang, Ting-Jung Chen
-
Patent number: 8354094Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.Type: GrantFiled: August 20, 2012Date of Patent: January 15, 2013Assignees: GP Medical, Inc., National Tsing Hua UniversityInventors: Hsing-Wen Sung, Kiran Sonaje, Zi-Xian Liao, Ha Giang Thi Nguyen, Er-Yuan Chuang, Hosheng Tu
-
Patent number: 8354093Abstract: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2?-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.Type: GrantFiled: October 14, 2005Date of Patent: January 15, 2013Assignee: Washington UniversityInventors: Matthew L. Becker, Huafeng Fang, Xiaoxu Li, Dipanjan Pan, Raffaella Rossin, Xiankai Sun, John-Stephen Taylor, Jeffrey L. Turner, Michael John Welch, Karen L. Wooley
-
Publication number: 20130011335Abstract: This invention is based in part on the elucidation of new structural conformations and functions of the sodium/potassium adenosine triphosphate synthase (Na/K ATPase), and especially elucidation of new binding sites and interactions. The present invention provides practical applications of several surprising structural and functional relationships between Na/K ATPase and compounds which interact with Na/K ATPase. Disclosure of these structures and relationships provides insight and practical solutions to chemically affecting not only the Na/K ATPase interactions, but also regulators known to be upstream and downstream.Type: ApplicationFiled: January 13, 2011Publication date: January 10, 2013Applicant: University of ToledoInventors: Zi-Jian Xie, Qiqi Ye, Zhichuan Li
-
Publication number: 20130011334Abstract: The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. The invention is further directed to the use of said proteins in medical treatment methods.Type: ApplicationFiled: December 14, 2010Publication date: January 10, 2013Inventors: Arnd Steuernagel, Erik Fiedler, Markus Fiedler, Anja Kunert, Joerg Nerkamp, Thomas Goettler, Manja Gloser, Ilka Haenssgen
-
Publication number: 20130004421Abstract: The invention provides a radiolabeled affibody molecule comprising a fragment of an IgG-binding domain of protein A from Staphylococcus aureus, a bifunctional linker, and a radiolabel comprising 18F or 76Br, wherein the bifunctional linker links the fragment and the radiolabel. The affibody molecule binds with high affinity to select receptors, which are over-expressed in certain cancers. Since the radionuclides emit a positron, the in vitro and in vivo binding characteristics of the radiolabeled affibody can be assessed using diagnostic imaging.Type: ApplicationFiled: September 10, 2012Publication date: January 3, 2013Applicant: The United States of America, as represented by the Secretary, Dept. of Health & Human ServicesInventors: Jacek Capala, Dale O. Kiesewetter, Gabriela Kramer-Marek, Sang Bong Lee
-
Publication number: 20130004420Abstract: The present invention relates to a compound having formula (I): wherein: X is in particular 125I Or 211At; R1 and R?1 are independently from each other chosen preferably from the group consisting of electron-withdrawing groups and alkyl groups; R2 is chosen from the group consisting of: H, alkyl groups, functional groups being able to bind a vector, and functional groups having targeting properties which make the compound of the invention a vector itself; Z is a heteroatom, R5, R8 and R9 are preferably H; Y is preferably an electron withdrawing group.Type: ApplicationFiled: February 20, 2011Publication date: January 3, 2013Inventors: Jean-Francois Gestin, Francois Guerard, Alain Faivre-Chauvet
-
Patent number: 8343461Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.Type: GrantFiled: August 29, 2008Date of Patent: January 1, 2013Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Jill Wykosky, Denise Gibo
-
Patent number: 8343927Abstract: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.Type: GrantFiled: September 13, 2010Date of Patent: January 1, 2013Assignee: Shire LLCInventors: Travis Mickle, Suma Krishnan, James Scott Moncrief, Christopher Lauderback
-
Patent number: 8343458Abstract: Activity-based probes, which are specific for certain active cysteine proteases (caspase, cathepsin and legumain) and carry radioactive labels, are disclosed. The present probes comprise an acyloxymethyketone (AOMK) “warhead” that binds only to active enzyme. The probes further comprise peptide-like structure that targets the probe to a specific cysteine protease or protease family, and a radiolabel on the probe, which is bound to the targeted enzyme. It has been found that the present probes are stable in vivo and give specific target images distinguishable over background. The preferred probes are labeled with a positron-emitting agent such as 64Cu, 125I (SPECT) and 99mTc (PET). The probes show in vivo half-life and stability well suited for imaging.Type: GrantFiled: April 3, 2009Date of Patent: January 1, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Matthew S. Bogyo, Galia Blum, Alicia Berger, Zhen Cheng, Sanjiv S. Gambhir
-
Publication number: 20120328515Abstract: The invention provides methods and products, such as kits, useful for determining the apoptotic state of cells in an organism.Type: ApplicationFiled: May 24, 2012Publication date: December 27, 2012Inventors: Gary L. Johnson, Brian W. Lee
-
Publication number: 20120328516Abstract: The present invention relates to a method of radiotherapy, in particular image-guided radiotherapy (IGRT), where radiolabelled RGD peptides are used to provide a tumour angiogenesis volume. Also provided are methods of determination of the gross tumour volume as well as methods of radiotherapy monitoring using such peptides.Type: ApplicationFiled: June 26, 2012Publication date: December 27, 2012Inventors: BRIAN J. MCPARLAND, JULIAN GOGGI
-
Publication number: 20120328517Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.Type: ApplicationFiled: August 9, 2012Publication date: December 27, 2012Applicant: Dyax Corp.Inventors: William Markland, Robert C. Ladner
-
Patent number: 8337810Abstract: Oxidants (e.g., N-chlorosuccinimide) can be used to stabilize ?-particle emitters (e.g., 211 At) in solution, prior to their subsequent reaction to form ?-particle emitter labeled compounds (e.g., a radiolabeled pharmaceutical or a radiolabeled pre-cursor used to prepare it). In particular, the use of an oxidant has been found to maintain the ?-particle emitter in a chemical form that facilitates this reaction, which may involve a number of possible mechanisms including electrophilic substitution, nucleophilic substitution, complexation, exchange, or metallic bonding. Compounds labeled with ?-particle emitters in this manner have wide-ranging therapeutic applications, particularly in the treatment of cancer.Type: GrantFiled: December 22, 2006Date of Patent: December 25, 2012Assignee: Duke UniversityInventors: Michael Rod Zalutsky, Oscar Rodolfo Pozzi
-
Patent number: 8337811Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.Type: GrantFiled: March 12, 2012Date of Patent: December 25, 2012Assignees: GP Medical, Inc., National Tsing Hua UniversityInventors: Hsing-Wen Sung, Kiran Sonaje, Ho-Ngoc Nguyen, Er-Yuan Chuang, Hosheng Tu
-
Patent number: 8337813Abstract: The present invention relates generally to multimodal magnetic resonance imaging (MRI) contrast agents. In particular, the present invention provides a MRI contrast agent configured to manipulate both the longitudinal (T1) and transverse (T2) relaxation times of surrounding water proton spins.Type: GrantFiled: September 15, 2008Date of Patent: December 25, 2012Assignee: Northwestern UniversityInventors: Elise A. Schultz Sikma, Mohammad Aslam, Vinayak P. Dravid, Thomas J. Meade, Bradley D. Ulrich
-
Patent number: 8338366Abstract: A nanoparticle-polypeptide complex comprising a bioactive polypeptide in association with a nanoparticle, wherein the bioactive polypeptide is modified by the addition of a chemical moiety that facilitates cellular uptake of the protein. The polypeptide can be a protein or a peptide. In some embodiments, the amino acid sequence of the protein or peptide is derived from the amino acid sequence of a tumor suppressor gene product.Type: GrantFiled: March 14, 2006Date of Patent: December 25, 2012Assignee: The Board of Regents of the University of the Texas SystemInventors: Jacki Lin, Ralph B. Arlinghaus, Tong Sun, Lin Ji, Bulent Ozpolat, Gabriel Lopez-Berestein, Jack A. Roth
-
Patent number: 8334253Abstract: The disclosure is directed to methods and compositions that include MNTF peptides and their analogs for cosmetic and dermatological purposes.Type: GrantFiled: February 23, 2009Date of Patent: December 18, 2012Assignee: Dermacare Neuroscience InstituteInventor: Pui-Yuk Dorothy Ko
-
Patent number: 8334000Abstract: An extract of Chinese blackberry (Rubus suavissimus) has been found to inhibit angiogenesis, and two active fractions isolated. Gallic acid was shown to be one of the active anti-angiogenic compounds by an in vitro human angiogenesis model. Aqueous extracts from other plants either known or found to have gallic acid were also found to have anti-angiogenic activity. Various derivatives of gallic acid were found to inhibit angiogenesis. The extract from Chinese blackberry also slowed the growth of a pancreatic tumor and of corneal neovascularization in rats. Extracts from pomegranate were shown to inhibit angiogenesis in fat tissue. Extracts from Rubus spp, and other plants with gallic acid, and gallic acid and its derivatives will be useful for treating various diseases associated with neovascularization, including diabetic retinopathy, psoriasis, tumors, obesity, cancer, rheumatoid arthritis, etc.Type: GrantFiled: March 22, 2010Date of Patent: December 18, 2012Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical CollegeInventors: Frank L. Greenway, Zhijun Liu, Eugene A. Woltering
-
Patent number: 8329863Abstract: Antagonistic peptides of GnRH having improved water solubility are disclosed. These peptides are capable of suppressing serum testosterone levels in vivo to chemical castration levels of ?0.5 ng/ml. Stable, filter sterilizable, non-gelling solutions containing the GnRH antagonists at least at levels typically used in sustained release formulations also are disclosed, as is a method of increasing the solubility of GnRH antagonist in a polymer containing dispersed phase, which method comprises addition of an acid to the dispersed phase.Type: GrantFiled: July 18, 2005Date of Patent: December 11, 2012Assignee: Oakwood Laboratories, LLCInventors: Bagavathikanun C. Thanoo, James Murtagh
-
Publication number: 20120308481Abstract: Radio-opaque biodegradable compositions are formed by modifying terminal groups of synthetic and natural biodegradable polymers such as polylactones with iodinated moieties. The biodegradable property of the compositions renders them suitable for use in medical field such as drug delivery, imaging. Compounds disclosed in this invention exist as neat liquid. Certain compositions disclosed in this invention form hydrophobic iodine rich domains when dissolved in water, such domains provide better contrasting properties as well as ability to dissolve hydrophobic bioactive drugs. Certain iodinated moieties disclosed in the invention are capable of cross linking natural proteins in situ in presence of suitable catalysts and co-catalysts.Type: ApplicationFiled: August 16, 2012Publication date: December 6, 2012Applicant: PATHAK HOLDINGS LLCInventors: Chandrashekhar P. Pathak, Sanjay M. Thigle
-
Patent number: 8324153Abstract: Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.Type: GrantFiled: May 5, 2009Date of Patent: December 4, 2012Assignee: New York Blood Center, Inc.Inventors: Asim Kumar Debnath, Hongtao Zhang, Francesca Curreli
-
Publication number: 20120301397Abstract: The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula Ab-X where the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.Type: ApplicationFiled: June 21, 2012Publication date: November 29, 2012Inventors: Philip S. Low, Mary Jo Turk
-
Publication number: 20120294802Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.Type: ApplicationFiled: May 21, 2012Publication date: November 22, 2012Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian Robert Kovacevich, John A. Latham, Jeffrey T.L. Smith, Leon F. Garcia-Martinez
-
Publication number: 20120294801Abstract: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.Type: ApplicationFiled: April 16, 2012Publication date: November 22, 2012Applicant: Yeda Research and Development Co., Ltd.Inventors: Avigdor Scherz, Yoram Salomon, Efrat Rubinstein, Alexander Brandis, Doron Eren, Karin Neimann
-
Publication number: 20120288442Abstract: A method for diagnosing liver fibrosis is provided. A monoclonal antibody and an antagonist of cannabinoid receptor in liver fibrosis cell are labeled. The monoclonal antibody or the antagonist is injected for nuclear imaging. Thus, through the image obtained through the nuclear imaging, liver fibrosis is diagnosed and traced in clinic use for preventive medicine.Type: ApplicationFiled: May 11, 2011Publication date: November 15, 2012Applicant: ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCHInventors: Chun-Chia Cheng, Shui-Cheng Lee, Pei-Chih Ku
-
Publication number: 20120282171Abstract: The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I) with a compound of formula (II): R*-L2-C?N+—O???(II) or, a compound of formula (III) with a compound of formula (IV) in the presence of a Cu (I) catalyst. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.Type: ApplicationFiled: June 25, 2012Publication date: November 8, 2012Applicant: HAMMERSMITH IMANET LIMITEDInventors: MATTHIAS EBERHARD GLASER, ERIK ARSTAD
-
Patent number: 8303933Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patient who is then diagnosed or treated using the effector molecule.Type: GrantFiled: July 12, 2010Date of Patent: November 6, 2012Assignee: Mallinckrodt LLCInventors: Gary L. Cantrell, B. Daniel Burleigh
-
Patent number: 8304388Abstract: The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A precursor for the preparation of the imaging agent is also provided by the invention, as well as a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical composition. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition which comprises fibrosis is provided.Type: GrantFiled: May 25, 2007Date of Patent: November 6, 2012Assignee: GE Healthcare LimitedInventors: Salah Chettibi, Ben Newton, Mette Husbyn, Magne Solbakken, Peter Brian Iveson, Rajiv Bhalla, Daniel Kramer, Jane Brown
-
Patent number: 8303932Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.Type: GrantFiled: July 12, 2010Date of Patent: November 6, 2012Assignee: Mallinckrodt LLCInventors: Gary L. Cantrell, B. Daniel Burleigh
-
Publication number: 20120276001Abstract: A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q1, X, Y, Z, Z1, m, n and r are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a metal ion, such as an ion of 90Y, 111In or 177Lu; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate. A method of therapeutic treatment of a mammal involving administration of the pharmaceutical composition is also described.Type: ApplicationFiled: May 21, 2012Publication date: November 1, 2012Applicant: Nordion (Canada) IncInventors: Zoltan Kovacs, Garry E. Kiefer, Corinne Bensimon, A. Dean Sherry, Gyula Tircso, Cara Ferreira
-
Patent number: 8293702Abstract: The present application relates to peptides which bind to tannin, polyphenolic or anthocyanin compounds, and particularly to tea and wine stains on a fabric or other surface. The invention also concerns binding peptide conjugates which includes a binding peptide coupled to an agent and the use of the binding peptide conjugate for delivering an agent to a desired target.Type: GrantFiled: June 23, 2008Date of Patent: October 23, 2012Assignee: Danisco US Inc.Inventors: Christopher J. Murray, Pilar Tijerina, Franciscus J. C. Van Gastel, Giselle G. Janssen
-
Patent number: 8293207Abstract: An amino acid analog is provided, in syn-stereoisomeric form, anti-stereoisomeric form, or a combination thereof. The amino acid analog includes a cyclobutane ring with at least one of an amine group and a carboxyl group attached to one carbon node of the cyclobutane ring. A chain of moieties X, Y, and Z attached to one of remaining three carbon nodes of the cyclobutane ring. X is a chelating agent selected from a group comprising DCTA, DOTA, DTPA, EDTA, NOTA, PCTA, and TETA. Y is a linking moiety selected from a group comprising —NH—CO— and —NH-p-CHSN-Bn- where the linking moiety facilitates incorporation of the chelating agent into the amino acid analog. Z is a metal radioisotope selected from a group comprising Cu-60, Cu-61, Cu-62, Cu-64, Cu-67, Ga-67, Ga-68, Y-86, Y-88, Y-90, Sr-85, Sr-89, Gd-153, Gd-157, Sm-153, Lu-177, W-185, Re-186, Re-188, and Ir-192.Type: GrantFiled: September 18, 2009Date of Patent: October 23, 2012Inventors: Valery Zavarzin, Irving Weinberg
-
Patent number: 8293206Abstract: The present disclosure provides methods for treating cancer in a patient in need of such treatment, the method includes prequalifying a patient's therapeutic treatment by performing a molecular imaging procedure to the patient using a labeled biomarker specific for a cancer target at the tumor site; and administering a therapeutic effective amount of a compound comprising a targeting agent linked to a chemotherapeutic or a targeting agent linked to an antibody. Embodiments of the present invention also include compounds and compositions for using such methods.Type: GrantFiled: June 1, 2009Date of Patent: October 23, 2012Assignee: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Kai Chen, Dhanalakshmi Kasi, Umesh B. Gangadharmath, Peter J. H. Scott, Gang Chen, Vani P. Mocharla